Budd-Chiari syndrome natural history, complications and prognosis: Difference between revisions
No edit summary |
Irfan Dotani (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Budd-Chiari syndrome}} | {{Budd-Chiari syndrome}} | ||
{{CMG}} | {{CMG}}; {{AE}} | ||
{{PleaseHelp}} | |||
==Overview== | |||
==Prognosis== | ==Prognosis== | ||
Several studies have attempted to predict the survival of patients with Budd-Chiari syndrome. In general, nearly 2/3 of patients with Budd-Chiari survive 10 years. <ref name="Murad">Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, van Hoek B, Hansen BE, Rosendaal FR, Janssen HL Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004 Feb;39(2):500-8.</ref> Important negative prognostic indicators include ascites, encephalopathy, elevated[[Child-Pugh score]]s, elevated [[prothrombin time]], and altered serum levels of various substances ([[sodium]], [[creatinine]],[[serum albumin|albumin]], and [[bilirubin]]). Survival is also highly dependent on the underlying cause of the Budd-Chiari syndrome. For example, patients with [[myeloproliferative disorder]]s may progress to acute leukemia despite treatment for Budd-Chiari syndrome. | Several studies have attempted to predict the survival of patients with Budd-Chiari syndrome. In general, nearly 2/3 of patients with Budd-Chiari survive 10 years. <ref name="Murad">Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, van Hoek B, Hansen BE, Rosendaal FR, Janssen HL Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004 Feb;39(2):500-8.</ref> Important negative prognostic indicators include ascites, encephalopathy, elevated[[Child-Pugh score]]s, elevated [[prothrombin time]], and altered serum levels of various substances ([[sodium]], [[creatinine]],[[serum albumin|albumin]], and [[bilirubin]]). Survival is also highly dependent on the underlying cause of the Budd-Chiari syndrome. For example, patients with [[myeloproliferative disorder]]s may progress to acute leukemia despite treatment for Budd-Chiari syndrome. | ||
==References== | ==References== | ||
{{Reflist|2}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category: | [[Category:Hepatology]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
{{WS}} | |||
{{WH}} | |||
Revision as of 17:35, 18 July 2016
|
Budd-Chiari syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Budd-Chiari syndrome natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Budd-Chiari syndrome natural history, complications and prognosis |
|
FDA on Budd-Chiari syndrome natural history, complications and prognosis |
|
CDC on Budd-Chiari syndrome natural history, complications and prognosis |
|
Budd-Chiari syndrome natural history, complications and prognosis in the news |
|
Blogs on Budd-Chiari syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Prognosis
Several studies have attempted to predict the survival of patients with Budd-Chiari syndrome. In general, nearly 2/3 of patients with Budd-Chiari survive 10 years. [1] Important negative prognostic indicators include ascites, encephalopathy, elevatedChild-Pugh scores, elevated prothrombin time, and altered serum levels of various substances (sodium, creatinine,albumin, and bilirubin). Survival is also highly dependent on the underlying cause of the Budd-Chiari syndrome. For example, patients with myeloproliferative disorders may progress to acute leukemia despite treatment for Budd-Chiari syndrome.
References
- ↑ Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, van Hoek B, Hansen BE, Rosendaal FR, Janssen HL Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004 Feb;39(2):500-8.